Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy

According to the World Health Organization (WHO), cancer is a leading cause of death worldwide. The identification of novel targets for cancer treatment is an area of intense work that has led Bcl-2 over-expression to be proposed as one of the hallmarks of cancer and Bcl-2 inhibition as a promising...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Aranda, Marilina, Pérez-Ruiz, Elisabet, Redondo, Maximino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321604/
https://www.ncbi.nlm.nih.gov/pubmed/30544835
http://dx.doi.org/10.3390/ijms19123950
Descripción
Sumario:According to the World Health Organization (WHO), cancer is a leading cause of death worldwide. The identification of novel targets for cancer treatment is an area of intense work that has led Bcl-2 over-expression to be proposed as one of the hallmarks of cancer and Bcl-2 inhibition as a promising strategy for cancer treatment. In this review, we describe the different pathways related to programmed cell death, the role of Bcl-2 family members in apoptosis resistance to anti-cancer treatments, and the potential utility of Bcl-2 inhibitors to overcome resistance to chemo- and immunotherapy.

Ejemplares similares